In April 2025, a large multi-center study was conducted by MedicQuant and KOL's in the field, analyzing patient samples from patients on Apixaban. The study was conducted on an international patient group, consisting of more than 180 patient samples from hospitals in several different countries. MedicQuant's point-of-care device and Apixaban cartridge were used to measure the patient samples. The attained results were benchmarked against centralized laboratory tests and LC-MS/MS (also known as the 'gold standard' in the field). Overall, the product demonstrated excellent performance on the tested patient samples similar to the centralized laboratory test.

This is the first time quantification of Apixaban, using a point-of-care device, has demonstrated similar performance to centralized laboratory tests on patient samples.